Summit Therapeutics stock crashed Friday after the company said its lung cancer treatment didn't pass muster at an interim analysis.

Tempus AI (TEM) stock gains after being named to TIME's influential health companies list, with Q1 earnings expected May 5 ...

A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda ...

US pharma major Merck reported first-quarter revenue of $16.3 billion, up 5%, while posting a GAAP loss of $1.72 per share ...

Merck faces falling sales for other key drugs including a blockbuster HPV vaccine and diabetes medication.

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some ...

Days after Sun Pharmaceutical Industries announced its $ 11.75 billion deal to acquire United States-based healthcare company ...

Sun Pharma will acquire US-based Organon & Co for $11.8 billion, expanding into women's health and biosimilars, nearly ...

Organon (NYSE:OGN), a women’s health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after ...

An early Moderna investor, Platinum Asset Management’s Bianca Ogden is leveraging fresh medical breakthroughs to ride a ...